{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:18:56Z","timestamp":1789996736070,"version":"4.0.1"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Non-tuberculous mycobacterial pulmonary disease (NTM-PD) is a refractory chronic respiratory infectious disease and its prevalence is increasing globally. The standard treatment regimen for NTM-PD involves long-term multidrug therapy including macrolides. The incidence of adverse events is high given the advanced age of many NTM-PD patients. In addition, drug\u2013drug interactions under coexisting conditions add additional complexity. Despite guidelines advocating multidrug therapy for NTM-PD, low adherence rates probably owing to the relatively frequent adverse events and drug interactions. An appropriate treatment regimen can improve the bacteriological response rates, reduce the development of macrolide resistance, and mitigate adverse events. Of particular concern are the interactions arising from new complications that develop with NTM-PD. Notably, chronic pulmonary aspergillosis occasionally co-infects NTM-PD, which can lead to poor prognosis. The primary therapeutic modality for chronic pulmonary aspergillosis is the azoles. However, the interaction with rifamycin is problematic, making it challenging to continue standard treatment for NTM-PD and requiring drug adjustments. The implications of rifamycin extend beyond chronic pulmonary aspergillosis, impacting various other diseases such as those requiring immunosuppressive agents and AIDS patients requiring antiretroviral therapy. Hence, a comprehensive consideration of drug interactions is imperative for the initiation of NTM-PD treatment. This mini-review focuses on drug\u2013drug interactions in a multidrug regimen for NTM-PD and discusses the essential points to be considered in the treatment of NTM.<\/jats:p>","DOI":"10.3389\/fmicb.2024.1468383","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T04:45:13Z","timestamp":1725511513000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Drug\u2013drug interactions in the management of non-tuberculous mycobacterial infections"],"prefix":"10.3389","volume":"15","author":[{"given":"Kazuaki","family":"Takeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Takazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1164\/rccm.201111-2016OC","article-title":"Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries","volume":"185","author":"Adjemian","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1513\/AnnalsATS.201304-085OC","article-title":"Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease","volume":"11","author":"Adjemian","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.resinv.2021.06.010","article-title":"Lower dose of ethambutol may reduce ocular toxicity without radiological deterioration for Mycobacterium avium complex pulmonary disease","volume":"59","author":"Ando","year":"2021","journal-title":"Respir. Investig."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/antibiotics9020072","article-title":"Rifabutin suppresses inducible clarithromycin resistance in Mycobacterium abscessus by blocking induction of whiB7 and erm41","volume":"9","author":"Aziz","year":"2020","journal-title":"Antibiotics (Basel)."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/315380","article-title":"Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196\/Terry Beirn community programs for clinical research on AIDS 009 protocol team","volume":"181","author":"Benson","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/infdis\/174.6.1218","article-title":"Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model","volume":"174","author":"Bermudez","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"790767","DOI":"10.3389\/fphar.2021.790767","article-title":"Omadacycline potentiates clarithromycin activity against Mycobacterium abscessus","volume":"12","author":"Bich Hanh","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1136\/thoraxjnl-2014-206470","article-title":"Increased risk of mycobacterial infections associated with anti-rheumatic medications","volume":"70","author":"Brode","year":"2015","journal-title":"Thorax"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/infdis\/jiw085","article-title":"Incidence of AIDS-defining opportunistic infections in a multicohort analysis of HIV-infected persons in the United States and Canada, 2000-2010","volume":"214","author":"Buchacz","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/00002030-199703110-00008","article-title":"Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection","volume":"11","author":"Chaisson","year":"1997","journal-title":"AIDS"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijid.2022.10.013","article-title":"Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review","volume":"125","author":"Dahl","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref90001","year":"2024"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1086\/514116","article-title":"A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California collaborative treatment group","volume":"176","author":"Dube","year":"1997","journal-title":"J. Infect. Dis."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/jac\/dku510","article-title":"beta-lactamase inhibition by avibactam in Mycobacterium abscessus","volume":"70","author":"Dubee","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1128\/AAC.02615-15","article-title":"Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin","volume":"60","author":"Ferro","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"ofw147","DOI":"10.1093\/ofid\/ofw147","article-title":"Preliminary evaluation of a Sitafloxacin-containing regimen for relapsed or refractory pulmonary Mycobacterium avium complex disease","volume":"3","author":"Fujita","year":"2016","journal-title":"Open Forum Infect Dis."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e0157922","DOI":"10.1128\/aac.01579-22","article-title":"In vitro synergistic effects of Omadacycline with other antimicrobial agents against Mycobacterium abscessus","volume":"67","author":"Fujiwara","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e0192821","DOI":"10.1128\/Spectrum.01928-21","article-title":"Minimum inhibitory concentrations before and after antibacterial treatment in patients with Mycobacterium abscessus pulmonary disease","volume":"9","author":"Fujiwara","year":"2021","journal-title":"Microbiol Spectr."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/microorganisms9020270","article-title":"New\/different look at the presence of aspergillus in mycobacterial pulmonary diseases. Long-term retrospective cohort study","volume":"9","author":"Fukushima","year":"2021","journal-title":"Microorganisms"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1128\/AAC.32.9.1400","article-title":"In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice","volume":"32","author":"Gangadharam","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1128\/AAC.00579-07","article-title":"Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications","volume":"51","author":"Geist","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1086\/514748","article-title":"A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex","volume":"28","author":"Gordin","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1128\/AAC.42.3.631","article-title":"Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers","volume":"42","author":"Hafner","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1093\/cid\/ciaa810","article-title":"Trends in the nontuberculous mycobacterial disease mortality rate in Japan: a Nationwide observational study, 1997-2016","volume":"73","author":"Harada","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"779531","DOI":"10.3389\/fmicb.2021.779531","article-title":"Sitafloxacin expresses potent anti-Mycobacterium abscessus activity","volume":"12","author":"He","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/00912709922007499","article-title":"Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers","volume":"39","author":"Hebert","year":"1999","journal-title":"J. Clin. Pharmacol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e0165023","DOI":"10.1128\/aac.01650-23","article-title":"Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants","volume":"17","author":"Hodges","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref31","first-page":"195","article-title":"Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on Mycobacterium avium complex","volume":"7","author":"Hoffner","year":"1989","journal-title":"Acta Leprol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1378\/chest.15-0543","article-title":"Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including Clofazimine and\/or rifampin","volume":"149","author":"Jarand","year":"2016","journal-title":"Chest"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s002280050437","article-title":"Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients","volume":"54","author":"Jaruratanasirikul","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1164\/rccm.201408-1545OC","article-title":"Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"191","author":"Jeong","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1164\/ajrccm\/140.1.264","article-title":"Ethambutol: a key for Mycobacterium avium complex chemotherapy?","volume":"140","author":"K\u00e4llenius","year":"1989","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"12208","DOI":"10.1038\/s41598-021-91757-4","article-title":"Nationwide surveillance of antimicrobial susceptibility of 509 rapidly growing mycobacteria strains isolated from clinical specimens in Japan","volume":"11","author":"Kamada","year":"2021","journal-title":"Sci. Rep."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e02623-18","DOI":"10.1128\/AAC.02623-18","article-title":"In vitro activity of the new beta-lactamase inhibitors Relebactam and Vaborbactam in combination with beta-lactams against Mycobacterium abscessus complex clinical isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/jac\/30.5.643","article-title":"The in-vitro bactericidal activities of combinations of antimicrobial agents against clinical isolates of Mycobacterium avium-intracellulare","volume":"30","author":"Kent","year":"1992","journal-title":"J. Antimicrob. Chemother."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e0077422","DOI":"10.1128\/aac.00774-22","article-title":"Outcomes of short-term Tigecycline-containing regimens for Mycobacterium abscessus pulmonary disease","volume":"66","author":"Kim","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e13893","DOI":"10.1111\/tid.13893","article-title":"Drug-level change and optimal dose adjustment of tacrolimus with the use of rifabutin for treating mycobacterial disease in solid organ transplant recipients","volume":"24","author":"Kim","year":"2022","journal-title":"Transpl. Infect. Dis."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.rmed.2006.04.002","article-title":"A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease","volume":"101","author":"Kobashi","year":"2007","journal-title":"Respir. Med."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10156-006-0457-8","article-title":"Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates","volume":"12","author":"Kobashi","year":"2006","journal-title":"J. Infect. Chemother."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1128\/AAC.02281-12","article-title":"Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen","volume":"57","author":"Koh","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41598-020-57844-8","article-title":"Effect of amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus","volume":"10","author":"Lopeman","year":"2020","journal-title":"Sci. Rep."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.rmed.2018.10.022","article-title":"Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population","volume":"145","author":"Marras","year":"2018","journal-title":"Respir. Med."},{"key":"ref46","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/bmj.286.6369.923","article-title":"Rifampicin reduces effectiveness and bioavailability of prednisolone","volume":"286","author":"McAllister","year":"1983","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1513\/AnnalsATS.201308-266OC","article-title":"Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study","volume":"11","author":"Miwa","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jiac.2017.02.004","article-title":"Effect of a 150 mg dose of rifabutin on serum itraconazole levels in patients with coexisting chronic pulmonary aspergillosis and Mycobacterium avium complex lung disease","volume":"23","author":"Moon","year":"2017","journal-title":"J. Infect. Chemother."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10067-011-1902-3","article-title":"Is continuation of anti-tumor necrosis factor-alpha therapy a safe option for patients who have developed pulmonary mycobacterial infection?: Case presentation and literature review","volume":"31","author":"Mori","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.rmed.2019.10.002","article-title":"Actual practice of standard treatment for pulmonary nontuberculous mycobacteriosis in Japan","volume":"158","author":"Morimoto","year":"2019","journal-title":"Respir. Med."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases","volume":"13","author":"Morimoto","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1134803","DOI":"10.3389\/fphar.2023.1134803","article-title":"Pharmacokinetic interaction of voriconazole and clarithromycin in Pakistani healthy male volunteers: a single dose, randomized, crossover, open-label study","volume":"14","author":"Mushtaq","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3201\/eid2206.151086","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan","volume":"22","author":"Namkoong","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/jac\/dkx311","article-title":"Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease","volume":"72","author":"Pasipanodya","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/jof6040346","article-title":"Chronic pulmonary Aspergillosis following nontuberculous mycobacterial infections: an emerging disease","volume":"6","author":"Phoompoung","year":"2020","journal-title":"J Fungi (Basel)."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"e00283-18","DOI":"10.1128\/AAC.00283-18","article-title":"Rifabutin acts in synergy and is bactericidal with frontline Mycobacterium abscessus antibiotics clarithromycin and Tigecycline, suggesting a potent treatment combination","volume":"62","author":"Pryjma","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1046\/j.1365-2125.2003.01996.x","article-title":"No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers","volume":"56","author":"Purkins","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"ofaa016","DOI":"10.1093\/ofid\/ofaa016","article-title":"Hope on the horizon: novel fungal treatments in development","volume":"7","author":"Rauseo","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1056\/NEJM199608083350602","article-title":"A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV trials network protocol 010 study group","volume":"335","author":"Shafran","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.chest.2023.05.036","article-title":"Open-label trial of amikacin liposome inhalation suspension in Mycobacterium abscessus lung disease","volume":"164","author":"Siegel","year":"2023","journal-title":"Chest"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/mmy\/myv093","article-title":"The risk factors for developing of chronic pulmonary aspergillosis in nontuberculous mycobacteria patients and clinical characteristics and outcomes in chronic pulmonary aspergillosis patients coinfected with nontuberculous mycobacteria","volume":"54","author":"Takeda","year":"2016","journal-title":"Med. Mycol."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cpdd.285","article-title":"Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of Isavuconazole with rifampin, ketoconazole, midazolam, and Ethinyl estradiol\/Norethindrone in healthy adults","volume":"6","author":"Townsend","year":"2017","journal-title":"Clin Pharmacol Drug Dev."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12890-020-01304-6","article-title":"Comorbidities associated with nontuberculous mycobacterial disease in Japanese adults: a claims-data analysis","volume":"20","author":"Uno","year":"2020","journal-title":"BMC Pulm. Med."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1164\/rccm.201204-0682OC","article-title":"The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment","volume":"186","author":"van Ingen","year":"","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"2302210","DOI":"10.1183\/13993003.02210-2023","article-title":"Rifampicin has no role in treatment of Mycobacterium avium complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint","volume":"63","author":"van Ingen","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"6324","DOI":"10.1128\/AAC.01505-12","article-title":"In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease","volume":"56","author":"van Ingen","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1601855","DOI":"10.1183\/13993003.01855-2016","article-title":"Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases","volume":"49","author":"van Ingen","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/fcp.12882","article-title":"Effects of clarithromycin on the pharmacokinetics of tacrolimus and expression of CYP3A4 and P-glycoprotein in rats","volume":"37","author":"Wen","year":"2023","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.3201\/eid1510.090310","article-title":"Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy","volume":"15","author":"Winthrop","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"e110922","DOI":"10.1371\/journal.pone.0110922","article-title":"Rheumatoid arthritis increases the risk of nontuberculosis mycobacterial disease and active pulmonary tuberculosis","volume":"9","author":"Yeh","year":"2014","journal-title":"PLoS One"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1038\/s41598-019-39665-6","article-title":"Short- and long-term risks of highly active antiretroviral treatment with incident opportunistic infections among people living with HIV\/AIDS","volume":"9","author":"Yen","year":"2019","journal-title":"Sci. Rep."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.chest.2023.11.038","article-title":"Safety and efficacy of Clofazimine as an alternative for rifampicin in Mycobacterium avium complex pulmonary disease treatment: outcomes of a randomized trial","volume":"165","author":"Zweijpfenning","year":"2024","journal-title":"Chest"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1468383\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T04:45:17Z","timestamp":1725511517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1468383\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":74,"alternative-id":["10.3389\/fmicb.2024.1468383"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2024.1468383","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"article-number":"1468383"}}